The foundation:

Merck discontinues the Verubecestat drug study


Merck discontinued the clinical trial of the Verubecestat drug performed in people with Alzheimer's at a very early stage. The pharmaceutical company has made this decision after the experimental drug did not give the expected results when it comes to inhibiting the production of beta-amyloid plaques, a protein that accumulates in the brains of people diagnosed with this disease. The results of the study were published in the New England Journal of Medicine.

The trial, carried out for two years by Fundació ACE, had the participation of a total of 1,454 people diagnosed with Alzheimer's at a very early stage in which the memory begins to fail but they still maintain their executive functions.


Commitment to Alzheimer's research

Despite the news, Fundació ACE continues with its commitment to help find a cure for Alzheimer's disease. "Despite this setback, we remain optimistic. We keep on thinking that we will soon find a cure for this disease. We will continue fighting dementia and working every day for our patients and their families", says Agustín Ruiz, head of research at Fundació ACE.

Currently, the Foundation participates in 16 clinical trials to find a cure for this disease that represents the most common type of dementia.



You might also like

FACEHBI study of early Alzheimer's detection expands

Fundació ACE will renew the FACEHBI study (ACE Healthy Brain Initivative Foundation) for three more years, an investigation that seeks to determine the relationship of subjective memory complaints as a risk factor in Alzheimer's disease.